Undisclosed ADC Programs

About TopAlliance Biosciences

TopAlliance Biosciences, founded in 2015 and headquartered in San Diego, is a clinical-stage biopharma developing targeted oncology therapies, most notably antibody-drug conjugates. As the US subsidiary of China's Junshi Biosciences, it benefits from a parent company with a proven track record in antibody development. The company has transitioned to a commercial-stage entity with the US and EU approval of its lead asset, toripalimab (LOQTORZI), for nasopharyngeal carcinoma, and maintains a broader pipeline of novel candidates.

About Hexagon Bio

Hexagon Bio is a private, preclinical-stage biotech founded in 2016 and headquartered in Menlo Park, California. The company is pioneering a novel platform to discover and develop new payloads for antibody-drug conjugates (ADCs), aiming to address the critical challenge of tumor resistance to current ADC therapies. With a leadership team boasting deep experience from Amgen, Gilead, and Genentech, Hexagon combines computational genomics and experimental biology to mine microbial genomes for novel bioactive molecules. Its goal is to expand the indication space for ADCs and deliver deeper, more durable responses for cancer patients.

About Myricx Bio

Myricx Bio is a private, preclinical-stage biotechnology company pioneering a first-in-class approach to antibody-drug conjugates (ADCs) by utilizing N-myristoyltransferase (NMT) inhibitors as cytotoxic payloads. Founded in 2020 and headquartered in London with a US presence in Boston, the company is backed by a strong syndicate of life science investors including Abingworth, Brandon Capital, and Novo Holdings. Under new CEO Mohit Rawat, who brings significant ADC and transaction expertise from Fusion Pharmaceuticals, Myricx is advancing its platform, which has shown compelling preclinical efficacy and safety across multiple solid tumor models.

About SystImmune

SystImmune is a private, preclinical-stage biotech focused on next-generation antibody therapeutics for oncology. The company leverages a platform for designing bi-specific, multi-specific antibodies and ADCs aimed at improving tumor targeting and immune system engagement. As a pre-revenue entity, its success hinges on advancing its pipeline through clinical validation and securing strategic partnerships or further investment. The competitive but high-reward oncology market presents a significant opportunity if its technology demonstrates superior efficacy or safety.

About Logomix

Japanese biotech developing precision antibody-drug conjugates using its proprietary LOGO-GATE platform for improved cancer therapies.

Therapeutic Areas

Other Oncology Drugs